The global oligonucleotide therapeutics market was valued at USD 7.2 billion in 2025 and is expected to reach USD 8.6 billion in 2026. The market is projected to expand significantly to USD 29.6 billion by 2033, registering a 19.4% CAGR from 2026 to 2033. North America represented the leading regional market, accounting for 47.6% of global revenue in 2025, while Asia Pacific is expected to record the fastest growth during the forecast period.

The market is undergoing substantial transformation as pharmaceutical and biotechnology companies increase investments in RNA-based medicines and gene-modulating therapies. Growing applications in rare genetic disorders, cancer, neurological diseases, and chronic conditions are broadening the commercial and clinical potential of oligonucleotide therapeutics.

What Is Driving the Oligonucleotide Therapeutics Market?

Several factors are contributing to the rapid expansion of this market:

• Growing adoption of RNA-targeting therapies: Clinical advances and successful commercialization of antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) therapies are encouraging pharmaceutical companies to increase investment in RNA therapeutics.
• Advances in drug-delivery technologies: Technologies such as N-acetylgalactosamine (GalNAc) conjugates and lipid nanoparticles are improving drug stability, tissue targeting, cellular uptake, and administration.
• Expansion of therapeutic applications: Oligonucleotide medicines are increasingly being investigated and commercialized for neurological disorders, oncology, genetic diseases, and other complex conditions.
• Increasing clinical and regulatory momentum: Expanding clinical pipelines, regulatory approvals, and commercialization of RNA-based medicines are strengthening confidence in nucleic acid therapeutics.
• Integration of AI and computational biology: AI-powered platforms are being used to identify therapeutic targets, design optimized oligonucleotide sequences, and accelerate preclinical development.

Download a free sample report or claim your copy of this full market intelligence report

Market Structure: Leading Segments and Regional Performance

The competitive landscape varies significantly across product classes, therapeutic applications, and administration routes.

Antisense oligonucleotides accounted for the largest share among oligonucleotide classes in 2025. Their established clinical applications and growing use in gene-modulating therapies are supporting segment leadership.

From a therapeutic-area perspective, neurology held the largest share at 41.1% in 2025, reflecting the increasing focus on RNA-based approaches for neurological and neurodegenerative diseases. Meanwhile, subcutaneous administration led by route of administration, with a 43.8% share, supported by the growing development of therapies designed for convenient patient administration.

Geographically, North America remained the dominant market in 2025 with a 47.6% revenue share. The U.S. held the largest country-level market share, supported by advanced biotechnology infrastructure, pharmaceutical investment, clinical research activity, and the presence of major RNA therapeutics companies. Asia Pacific is anticipated to be the fastest-growing regional market from 2026 to 2033, creating additional opportunities for manufacturers and drug developers.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Technology, AI, and Innovation Outlook

Innovation in oligonucleotide therapeutics is extending beyond drug discovery into delivery, manufacturing, automation, and precision medicine. Advances in ASOs, siRNA therapeutics, lipid nanoparticles, and GalNAc conjugation technologies are helping address historical challenges associated with stability, tissue-specific delivery, cellular uptake, and therapeutic efficiency.

Artificial intelligence is becoming an increasingly important component of the drug-development ecosystem. Pharmaceutical and biotechnology companies are deploying AI-enabled systems to improve target identification, oligonucleotide sequence design, candidate prioritization, preclinical research, and development timelines. Computational biology and automated laboratory platforms are also supporting more data-driven development workflows.

An example of this trend emerged in May 2026, when Insilico Medicine and Suzhou Ribo Life Science entered a strategic collaboration focused on accelerating RNA interference and oligonucleotide therapeutics development through AI-driven drug discovery and automated laboratory technologies. This type of collaboration illustrates the industry's broader movement toward integrating AI, automation, and RNA biology to improve research efficiency and advance next-generation nucleic acid therapeutics.

The competitive environment is also encouraging strategic partnerships and platform expansion. RNA-focused biotechnology companies are increasingly collaborating with technology and drug-discovery specialists to strengthen therapeutic pipelines, improve development efficiency, and expand their precision medicine capabilities.

Market Forecast at a Glance

The oligonucleotide therapeutics market is positioned for rapid long-term expansion:

• 2025 market value: USD 7.2 billion
• 2026 estimated value: USD 8.6 billion
• 2033 projected value: USD 29.6 billion
• 2026–2033 CAGR: 19.4%
• 2025 leading region: North America, with 47.6% revenue share
• 2026–2033 fastest-growing region: Asia Pacific

Overall, the outlook for the global oligonucleotide therapeutics market remains strong as clinical validation, regulatory progress, advanced delivery systems, and AI-enabled drug discovery converge. Continued investment in RNA-targeting medicines and precision therapeutics is expected to create new opportunities across neurological disorders, genetic diseases, oncology, and other high-value therapeutic areas.

Leading Oligonucleotide Therapeutics Companies

The key companies profiled in the oligonucleotide therapeutics market include:

• Ionis Pharmaceuticals
• Alnylam Pharmaceuticals
• Sarepta Therapeutics
• Biogen
• Novartis
• Roche
• Arrowhead Pharmaceuticals

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Explore our dedicated business services:

• S. Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.